Skip to main navigation menu Skip to main content Skip to site footer

Viewpoint

Vol. 141 No. 5152 (2011)

Artificial muscle: facts and fiction

  • MC Schaub
DOI
https://doi.org/10.4414/smw.2011.13319
Cite this as:
Swiss Med Wkly. 2011;141:w13319
Published
19.12.2011

Summary

Mechanical devices are sought to support insufficient or paralysed striated muscles including the failing heart. Nickel-titanium alloys (nitinol) present the following two properties: (i) super-elasticity, and (ii) the potential to assume different crystal structures depending on temperature and/or stress. Starting from the martensite state nitinol is able to resume the austenite form (state of low potential energy and high entropy) even against an external resistance. This one-way shape change is deployed in self-expanding vascular stents. Heating induces the force generating transformation from martensite to the austenite state while cooling induces relaxation back to the martensite state. This two-way shape change oscillating between the two states may be used in cyclically contracting support devices of silicon-coated nitinol wires. Such a contractile device sutured to the right atrium has been tested in vitro in a bench model and in vivo in sheep. The contraction properties of natural muscles, specifically of the myocardium, and the tight correlation with ATP production by oxidative phosphorylation in the mitochondria is briefly outlined. Force development by the nitinol device cannot be smoothly regulated as in natural muscle. Its mechanical impact is forced onto the natural muscle regardless of the actual condition with regard to metabolism and Ca2+-homeostasis. The development of artificial muscle on the basis of nitinol wires is still in its infancy. The nitinol artificial muscle will have to prove its viability in the various clinical settings.

References

  1. Tozzi P. Artificial muscle: the human chimera is the future. Swiss Med Wkly. 2011;141:w13311.
  2. Huxley HE. Fifty years of muscle and sliding filament hypothesis. Eur J Biochem. 2004;271:1403–15.
  3. Geeves MA, Holmes KC. Structural mechanism of muscle contraction. Annu Rev Biochem. 1999;68:687–728.
  4. Finer JT, Simmons RM, Spudich JA. Single myosin molecule mechanics: piconewton forces and nanometre steps. Nature. 1994;368:113–9.
  5. Linke WA. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res. 2008;77:637–48.
  6. Dobson GP. On being the right size: heart design, mitochondrial efficiency and lifespan potential. Clin Exp Pharmacol Physiol. 2003;30:590–7.
  7. Woledge RC, Curtin NA, Homsher E. Energetic aspects of muscle contraction. Academic Press, London 1985.
  8. Gibbs CL, Loiselle DS. Cardiac basal metabolism. Jap J Physiol. 2001;51:399–426.
  9. Schaub MC, Heizmann CW. Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem Biophys Res Commun. 2008;369:247–64.
  10. Schaub MC, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol. 2006;41:183–214.
  11. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135–45.
  12. Neubauer S. The failing heart – An engine out of fuel. N Engl J Med. 2007;356:1140–51.
  13. Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci USA. 2002;99:10237–9.
  14. Balaban RS. The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta. 2009;1787:1334–41.
  15. Beer M, Seyfarth T, Sandstede J, Landschütz W, Lipke C, Köstler H, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267–74.
  16. Ingwall JS. Energy metabolism in heart failure and remodeling. Cardiovasc Res. 2009;81:412–9.
  17. Ebron VH, Yang Z, Seyer DJ, Kozlov ME, Oh J, Xie H, et al. Fuel-powered artificial muscles. Science. 2006;311:1580–3.
  18. Stoeckel D, Pelton A, Duerig T. Self-expanding nitinol stents: material and design considerations. Eur Radiol. 2004;14:292–301.
  19. Dotter CT, Buschmann PAC, McKinney MK, Rösch J. Transluminal expandable nitinol coil stent grafting: preliminary report. Radiology. 1983;147:259–60.
  20. Pelton AR, Russell SM, DiCello J. The physical metallurgy of nitinol for medical applications. J Minerals Metals Materials (JOM-US). 2003;55:33–7.
  21. Tozzi P, Hayoz D, Taub S, Muradbegovic M, Rizzo E, et al. Biometal muscle to restore atrial transport function in a permanent atrial fibrillation animal model: a potential tool in the treatment of end-stage heart failure. Eur J Cardio Thorac Surg. 2010;37:870–4.
  22. Neuberger HR, Mewis C, Van Veldhuisen DJ, Schotten U, Van Gelder IC, Allessie MA, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J. 2007;28:2568–77.
  23. Schwientek P, Ellinghaus P, Steppen S, D’Urso D, Seewald M, Kassner A, et al. Global gene expression analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile ventricular assist device support. Physiol Genomics. 2010;42:397–405.